113 related articles for article (PubMed ID: 7617523)
1. Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo.
Tokui T; Maeda N; Kuroiwa C; Sasagawa K; Inoue T; Kawai K; Ikeda T; Komai T
Pharm Res; 1995 Mar; 12(3):370-5. PubMed ID: 7617523
[TBL] [Abstract][Full Text] [Related]
2. Contribution of serum lipoproteins as carriers of antitumour agent RS-1541 (palmitoyl rhizoxin) in mice.
Tokui T; Kuroiwa C; Tokui Y; Sasagawa K; Kawai K; Kobayashi T; Ikeda T; Komai T
Biopharm Drug Dispos; 1994 Mar; 15(2):93-107. PubMed ID: 8011970
[TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.
Hendriks HR; Plowman J; Berger DP; Paull KD; Fiebig HH; Fodstad O; Dreef-van der Meulen HC; Henrar RE; Pinedo HM; Schwartsmann G
Ann Oncol; 1992 Nov; 3(9):755-63. PubMed ID: 1450065
[TBL] [Abstract][Full Text] [Related]
4. Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells.
Takatori T; Koizumi T; Tokui T; Mitsuhashi Y; Shiraishi A; Tsuruo T
Cancer Chemother Pharmacol; 1995; 35(4):283-90. PubMed ID: 7828270
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice.
Kurihara A; Shibayama Y; Mizota A; Yasuno A; Ikeda M; Sasagawa K; Kobayashi T; Hisaoka M
Pharm Res; 1996 Feb; 13(2):305-10. PubMed ID: 8932454
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.
Arioka H; Nishio K; Heike Y; Abe S; Saijo N
J Cancer Res Clin Oncol; 1997; 123(4):195-200. PubMed ID: 9177491
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats.
Kurihara A; Shibayama Y; Mizota A; Yasuno A; Ikeda M; Hisaoka M
Biol Pharm Bull; 1996 Feb; 19(2):252-8. PubMed ID: 8850317
[TBL] [Abstract][Full Text] [Related]
8. Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues.
Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y; Haraguchi-Hiraoka T; Nagano H
J Antibiot (Tokyo); 1987 Jan; 40(1):66-72. PubMed ID: 3606749
[TBL] [Abstract][Full Text] [Related]
9. Delivery and cytotoxicity of RS-1541 in St-4 human gastric cancer cells in vitro by the low-density-lipoprotein pathway.
Tokui T; Takatori T; Shinozaki N; Ishigami M; Shiraishi A; Ikeda T; Tsuruo T
Cancer Chemother Pharmacol; 1995; 36(1):1-6. PubMed ID: 7720169
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
Graham MA; Bissett D; Setanoians A; Hamilton T; Kerr DJ; Henrar R; Kaye SB
J Natl Cancer Inst; 1992 Apr; 84(7):494-500. PubMed ID: 1545439
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of angiogenesis by rhizoxin, a microbial metabolite containing two epoxide groups.
Onozawa C; Shimamura M; Iwasaki S; Oikawa T
Jpn J Cancer Res; 1997 Dec; 88(12):1125-9. PubMed ID: 9473728
[TBL] [Abstract][Full Text] [Related]
12. Interaction of rhizoxin with bovine brain tubulin.
Sullivan AS; Prasad V; Roach MC; Takahashi M; Iwasaki S; Ludueña RF
Cancer Res; 1990 Jul; 50(14):4277-80. PubMed ID: 2364385
[TBL] [Abstract][Full Text] [Related]
13. Studies on macrocyclic lactone antibiotics. XIII. Anti-tubulin activity and cytotoxicity of rhizoxin derivatives: synthesis of a photoaffinity derivative.
Kato Y; Ogawa Y; Imada T; Iwasaki S; Shimazaki N; Kobayashi T; Komai T
J Antibiot (Tokyo); 1991 Jan; 44(1):66-75. PubMed ID: 2001986
[TBL] [Abstract][Full Text] [Related]
14. Species variation in pharmacokinetics and opsonization of palmitoyl rhizoxin (RS-1541) incorporated in lipid emulsions.
Kurihara A; Shibayama Y; Kasuya A; Ikeda M; Hisaoka M
J Drug Target; 1998; 5(6):491-505. PubMed ID: 9783680
[TBL] [Abstract][Full Text] [Related]
15. [Effect of sarcolysin and asalin on the incorporation of thymidine-H3 in the DNA of sarcoma 45 and tissues of tumor-bearing rats].
Struchkov VA; Bergol'ts VV
Biull Eksp Biol Med; 1976 May; 81(5):589-91. PubMed ID: 947383
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of rhizoxin.
Bissett D; Graham MA; Setanoians A; Chadwick GA; Wilson P; Koier I; Henrar R; Schwartsmann G; Cassidy J; Kaye SB
Cancer Res; 1992 May; 52(10):2894-8. PubMed ID: 1581905
[TBL] [Abstract][Full Text] [Related]
17. Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines.
Tsuruo T; Oh-hara T; Iida H; Tsukagoshi S; Sato Z; Matsuda I; Iwasaki S; Okuda S; Shimizu F; Sasagawa K
Cancer Res; 1986 Jan; 46(1):381-5. PubMed ID: 3753552
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
19. Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
McLeod HL; Murray LS; Wanders J; Setanoians A; Graham MA; Pavlidis N; Heinrich B; ten Bokkel Huinink WW; Wagener DJ; Aamdal S; Verweij J
Br J Cancer; 1996 Dec; 74(12):1944-8. PubMed ID: 8980394
[TBL] [Abstract][Full Text] [Related]
20. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
Takigawa N; Ohnoshi T; Ueoka H; Horiguchi T; Kiura K; Tabata M; Segawa Y; Shibayama T; Genba K; Matsumura T
Gan To Kagaku Ryoho; 1993 Jul; 20(9):1221-6. PubMed ID: 8392827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
